Literature DB >> 22617231

Seminal plasma proteins in prostatic carcinoma: increased nuclear semenogelin I expression is a predictor of biochemical recurrence after radical prostatectomy.

Koji Izumi1, Yi Li, Yichun Zheng, Jennifer Gordetsky, Jorge L Yao, Hiroshi Miyamoto.   

Abstract

Semenogelins and eppin are seminal plasma proteins that form a complex and inhibit sperm motility. However, the role of these proteins in prostate cancer is poorly understood. We immunohistochemically stained for semenogelins I and II and eppin in 291 radical prostatectomy specimens. We then evaluated the association between their expressions in nuclei, cytoplasms, or intraluminal secretions of benign/high-grade prostatic intraepithelial neoplasia/carcinoma cells and clinicopathologic profile available for our patient cohort. Stains were positive in 32%/77%/84% (nuclear semenogelin I), 87%/94%/84% (nuclear semenogelin II), 56%/64%/37% (nuclear eppin), 7%/15%/11% (cytoplasmic semenogelin I), 6%/11%/9% (cytoplasmic semenogelin II), 68%/74%/95% (cytoplasmic eppin), 97%/98%/13% (secreted semenogelin I), 98%/97%/11% (secreted semenogelin II), and 97%/98%/48% (secreted eppin) of benign/prostatic intraepithelial neoplasia/carcinoma, respectively. The levels of nuclear semenogelin I/cytoplasmic eppin were significantly higher in carcinoma than in benign (P<.001/P<.001) or prostatic intraepithelial neoplasia (P<.001/P<.001) and in prostatic intraepithelial neoplasia than in benign (P<.001/P=.006). Significantly higher nuclear semenogelin II expression was found in prostatic intraepithelial neoplasia than in benign (P<.001) or carcinoma (P<.001). Significantly lower nuclear eppin expression was seen in carcinoma than in benign (P<.001) or prostatic intraepithelial neoplasia (P<.001). Secreted semenogelin I, secreted semenogelin II, and secreted eppin were all significantly lower in carcinoma than in benign (P<.001) or prostatic intraepithelial neoplasia (P<.001). There were no statistically significant correlations between each stain and clinicopathologic features except significantly lower nuclear eppin expression in Gleason score 8 or higher tumors. Kaplan-Meier and log-rank tests further revealed that patients with nuclear semenogelin I-positive tumor had a significantly higher risk for biochemical recurrence (P=.046). Multivariate Cox model showed a trend toward significance (P=.093) in nuclear semenogelin I positivity as an independent predictor for recurrence. These results suggest that nuclear semenogelin I expression could be a reliable prognosticator in men who undergo radical prostatectomy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22617231     DOI: 10.1016/j.humpath.2012.02.008

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  10 in total

1.  Seminal plasma protein in renal cell carcinoma: expression of semenogelin I is a predictor for cancer progression and prognosis.

Authors:  Shengli Zhang; Jianzheng Fang; Xiangxiang Zhang; Chao Qin; Shifeng Su; Yunfei Deng; Zhen Song; Yi Zhang; Hainan Wang; Changjun Yin; Zengjun Wang
Journal:  Tumour Biol       Date:  2014-06-11

2.  Semenogelin I promotes prostate cancer cell growth via functioning as an androgen receptor coactivator and protecting against zinc cytotoxicity.

Authors:  Hitoshi Ishiguro; Koji Izumi; Eiji Kashiwagi; Yichun Zheng; Yi Li; Takashi Kawahara; Hiroshi Miyamoto
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

Review 3.  Review on NAD(P)H dehydrogenase quinone 1 (NQO1) pathway.

Authors:  S Preethi; K Arthiga; Amit B Patil; Asha Spandana; Vikas Jain
Journal:  Mol Biol Rep       Date:  2022-03-28       Impact factor: 2.742

4.  Estrogen receptor α in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3.

Authors:  Spencer Slavin; Chiuan-Ren Yeh; Jun Da; Shengqiang Yu; Hiroshi Miyamoto; Edward M Messing; Elizabeth Guancial; Shuyuan Yeh
Journal:  Carcinogenesis       Date:  2013-12-28       Impact factor: 4.944

Review 5.  Emerging roles of cancer-testis antigenes, semenogelin 1 and 2, in neoplastic cells.

Authors:  Oleg Shuvalov; Alyona Kizenko; Alexey Petukhov; Olga Fedorova; Alexandra Daks; Nikolai Barlev
Journal:  Cell Death Discov       Date:  2021-05-08

6.  The Differential Effects of Anti-Diabetic Thiazolidinedione on Prostate Cancer Progression Are Linked to the TR4 Nuclear Receptor Expression Status.

Authors:  Shin-Jen Lin; Chang-Yi Lin; Dong-Rong Yang; Kouji Izumi; Emily Yan; Xiaodan Niu; Hong-Chiang Chang; Hiroshi Miyamoto; Nancy Wang; Gonghui Li; Chawnshang Chang
Journal:  Neoplasia       Date:  2015-04       Impact factor: 5.715

7.  The interaction between androgen receptor and semenogelin I: a synthetic LxxLL peptide antagonist inhibits the growth of prostate cancer cells.

Authors:  Peng Li; Jinbo Chen; Eiji Kashiwagi; Taichi Mizushima; Bin Han; Satoshi Inoue; Hiroki Ide; Koji Izumi; Hiroshi Miyamoto
Journal:  Br J Cancer       Date:  2017-11-14       Impact factor: 7.640

8.  Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer.

Authors:  Meenal Sharma; Zhiming Yang; Hiroshi Miyamoto
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

9.  SEMG1/2 augment energy metabolism of tumor cells.

Authors:  Oleg Shuvalov; Alyona Kizenko; Alexey Petukhov; Olga Fedorova; Alexandra Daks; Andrew Bottrill; Anastasiya V Snezhkina; Anna V Kudryavtseva; Nikolai Barlev
Journal:  Cell Death Dis       Date:  2020-12-11       Impact factor: 8.469

10.  Attenuation of NAD[P]H:quinone oxidoreductase 1 aggravates prostate cancer and tumor cell plasticity through enhanced TGFβ signaling.

Authors:  Dinesh Thapa; Shih-Bo Huang; Amanda R Muñoz; Xiaoyu Yang; Roble G Bedolla; Chia-Nung Hung; Chun-Liang Chen; Tim H-M Huang; Michael A Liss; Robert L Reddick; Hiroshi Miyamoto; Addanki P Kumar; Rita Ghosh
Journal:  Commun Biol       Date:  2020-01-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.